While NME1 is somewhat differentially overexpressed in MYCN amplified neuroblastoma (logFC = 1, adjusted p-value = 1.17 × 10−6, Table S1) the protein product of NME1, nm23-H1, has diffuse sub-cellular localization that does not always include the plasma membrane (38) and mostly consists of the cytosol and endoplasmic reticulum (39), suggesting it would not be an ideal candidate for targeted immunotherapy. This evidence concerns the gene MYCN and neuroblastoma.